EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder

Jill A Dever iD, Marci F Hertz, Laura J Dunlap, John S Richardson, Sara Beth Wolicki, Bradley B Biggers, Mark J Edlund, Michele K Bohm, Didier Turcios, Xinyi Jiang, Hong Zhou, Mary E Evans und 1 weitere

Public Health Reports® · 2024

DOI: 10.1177/00333549231222479 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Public Health Reports®, 2024. Verfasst von Jill A Dever und 12 weiteren Autor:innen. Beteiligte Einrichtung: RTI International, Washington, DC, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Opioid use disorder (OUD) affects approximately 5.6 million people in the United States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are low. We conducted an observational cohort study from August 2017 through May 2021, the MOUD Study, to better understand treatment engagement and factors that may influence treatment experiences and outcomes. In this article, we describe the study design, data collected, and treatment outcomes.

Methods

We recruited adult patients receiving OUD treatment at US outpatient facilities for the MOUD Study. We collected patient-level data at 5 time points (baseline to 18 months) via self-administered questionnaires and health record data. We collected facility-level data via questionnaires administered to facility directors at 2 time points. Across 16 states, 62 OUD treatment facilities participated, and 1974 patients enrolled in the study. We summarized descriptive data on the characteristics of patients and OUD treatment facilities and selected treatment outcomes.

Results

Approximately half of the 62 facilities were private, nonprofit organizations; 62% focused primarily on substance use treatment; and 20% also offered mental health services. Most participants were receiving methadone (61%) or buprenorphine (32%) and were predominately non-Hispanic White (68%), aged 25-44 years (62%), and female (54%). Compared with patient-reported estimates at baseline, 18-month estimates suggested that rates of abstinence increased (55% to 77%), and rates of opioid-related overdoses (7% to 2%), emergency department visits (9% to 4%), and arrests (15% to 7%) decreased.

Conclusions

Our results demonstrated the benefits of treatment retention not only on abstinence from opioid use but also on other quality-of-life metrics, with data collected during an extended period. The MOUD Study produced rich, multilevel data that can lay the foundation for an evidence base to inform OUD treatment and support improvement of care and patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersOpiate Substitution TreatmentHumansFemaleMaleAdultUnited StatesMiddle AgedBuprenorphineMethadoneAnalgesics, OpioidTreatment OutcomeCohort StudiesSurveys and Questionnaires

Stichwörter der Autor:innen

MOUDbuprenorphinemethadonenaltrexoneopioid use disorder (OUD)outpatient treatment

Substanzen

BuprenorphineMethadoneAnalgesics, Opioid

Autor:innen und Institutionen

  • RTI International, Washington, DC, USA.
  • Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • RTI International, Research Triangle Park, NC, USA.
  • Current affiliation: Stop Soldier Suicide, Durham, NC, USA.

ORCID-Profile: Jill A Dever

Förderung

  • Intramural CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Dever, J. A., Hertz, M. F., Dunlap, L. J., Richardson, J. S., Wolicki, S. B., Biggers, B. B., Edlund, M. J., Bohm, M. K., Turcios, D., Jiang, X., Zhou, H., Evans, M. E., & Guy, G. P. (2024). The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder. Public Health Reports®. https://doi.org/10.1177/00333549231222479

Vancouver

Dever JA, Hertz MF, Dunlap LJ, Richardson JS, Wolicki SB, Biggers BB, et al. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder. Public Health Reports®. 2024. doi:10.1177/00333549231222479

BibTeX
@article{Dever2024,
  author = {Dever, Jill A and Hertz, Marci F and Dunlap, Laura J and Richardson, John S and Wolicki, Sara Beth and Biggers, Bradley B and Edlund, Mark J and Bohm, Michele K and Turcios, Didier and Jiang, Xinyi and Zhou, Hong and Evans, Mary E and Guy, Gery P},
  title = {The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder},
  journal = {Public Health Reports®},
  year = {2024},
  doi = {10.1177/00333549231222479}
}
Kostenlos starten →